Research → Comparative effectiveness research
Comparative effectiveness research
Our comparative effectiveness work is built on the target trial emulation framework: we specify the randomized trial that would answer a clinical question, then emulate its design as closely as real-world data allow. Matching the design to the question — rather than fitting every question to one familiar design — is what makes an estimate interpretable, and what makes the limits of the data explicit when they cannot support a causal claim. The aim is practical evidence — findings specific enough to inform how a medicine is chosen, sequenced, or stopped for an individual patient.
Selected work
- Comparative safety of potassium-competitive acid blockers on the risk of Clostridium difficile infection: a multicenter cohort study. American Journal of Gastroenterology, 2026.
- Timing of antidiabetic medication initiation and risk of cardiovascular events and mortality. JAMA Network Open, 2026.
- Effect of anemia developed after ruxolitinib initiation on adverse outcomes in patients with myelofibrosis: a nationwide cohort study. Blood Cancer Journal, 2026.
- Glucagon-like peptide-1 receptor agonists and risk of osteoarthritis among individuals with type 2 diabetes: a population-based cohort study. Diabetes Research and Clinical Practice, 2026.
- Cardiovascular, cancer, and infection risks of Janus kinase inhibitors in rheumatoid arthritis and ulcerative colitis: a nationwide cohort study. Journal of Internal Medicine, 2025.